Dashboard
1
With a fall in EPS of -49.88%, the company declared Very Negative results in Mar 25
- The company has declared negative results for the last 2 consecutive quarters
- The company has declared negative results in Dec 24 after 5 consecutive negative quarters
- NET SALES(Q) At CNY 204.14 MM has Fallen at -27.11%
- PRE-TAX PROFIT(Q) Fallen at -35.88%
- NET PROFIT(Q) Fallen at -35.1%
2
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 923 Million (Small Cap)
6.00
NA
0.00%
-0.91
7.76%
0.46
Revenue and Profits:
Net Sales:
69 Million
(Quarterly Results - Jun 2025)
Net Profit:
30 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.88%
0%
0.88%
6 Months
-3.05%
0%
-3.05%
1 Year
-24.23%
0%
-24.23%
2 Years
6.79%
0%
6.79%
3 Years
-16.07%
0%
-16.07%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Innovita Biological Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.40%
EBIT Growth (5y)
28.97%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.96
Sales to Capital Employed (avg)
0.27
Tax Ratio
8.78%
Dividend Payout Ratio
30.94%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
128.44%
ROE (avg)
9.63%
Valuation key factors
Factor
Value
P/E Ratio
6
Industry P/E
Price to Book Value
0.46
EV to EBIT
-6.73
EV to EBITDA
-5.44
EV to Capital Employed
-5.34
EV to Sales
-1.96
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
7.76%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
69.10
138.70
-50.18%
Operating Profit (PBDIT) excl Other Income
29.00
64.70
-55.18%
Interest
0.00
0.00
Exceptional Items
3.00
-0.40
850.00%
Consolidate Net Profit
29.80
60.20
-50.50%
Operating Profit Margin (Excl OI)
291.90%
413.30%
-12.14%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -50.18% vs 56.72% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -50.50% vs 155.08% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
616.60
474.80
29.87%
Operating Profit (PBDIT) excl Other Income
264.20
210.50
25.51%
Interest
0.20
0.30
-33.33%
Exceptional Items
7.10
-10.90
165.14%
Consolidate Net Profit
246.90
173.90
41.98%
Operating Profit Margin (Excl OI)
380.20%
374.00%
0.62%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 29.87% vs 8.48% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 41.98% vs 15.39% in Dec 2023
About Innovita Biological Technology Co., Ltd. 
Innovita Biological Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






